>> Dr. Mitchell E. Geffner, a professor of pediatrics at the University of Southern California, said the advantages of Iplex were ‘more theoretical than real,’ and that it would probably not make a difference to patients if they had to switch to Tercica's drug. <<
Evidently, this view was on target.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”